Big Pharma CEOs Descend On China: What’s The Likely Agenda?
Executive Summary
In a major show of force, four global pharma CEOs are heading to China to participate in high-level open and closed-door discussions that are expected to include a range of policy and regulatory reform topics. Tapping into China’s push to improve health and develop an innovation-driven economy may provide new openings for their voices to be heard.
You may also be interested in...
Now Is The Time! Rule Changes To Smooth China New Drug Approvals?
The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to quicken the pace of launches to potentially overcome China’s “drug lag” and that may also bolster multinationals’ interest and activity in the country.
Now Is The Time! Rule Changes To Open Up China To Foreign New Drugs?
The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to bolster multinationals’ interest and activity in China, and to quicken the pace of launches to potentially overcome the country’s “drug lag”.
Foreign Drugs Welcome As China Reforms Progress: CFDA Commissioner
China’s drug regulators have had plenty of views to offer at recent major government congress sessions in Beijing, which provide a forum for the industry to meet officials and opportunities to outline reform progress and planned policies.